Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia

Antibody nanoworms FLT3-A192 and CD99-A192 induce apoptosis and cell death. A–D, Trypan blue staining detects a decrease in cell viability across different cell lines FLT3-ITD+/CD99⁺ AML cells (MV4-11, MOLM-13), FLT3−/CD99⁺ cells (U937), and FLT3WT+/CD99⁻ (THP-1). In MV4-11, co-assembling CD99-A192 and FLT3-A192 further reduced viability compared to a combination “mixture” of/or single-targeted nanoworms. E and F, Greater levels of apoptosis (quadrant Q2) were observed by flow cytometry in MV4-11 cells treated with FLT3-A192, CD99-A192, and Co-Assembled formulations. G and H, In THP-1 cells levels of apoptosis did not change between the different treatment groups. I, The CCK-8 assay was used to quantify the dose-dependent cell viability in MV4-11 cells. Nonlinear curve fitting was used to estimate the IC₅₀, which showed that Co-Assembled CD99-A192 and FLT3-A192 (0.2 μmol/L) was more potent than FLT3-A192 (1.7 μmol/L) and CD99-A192 (0.4 μmol/L) by itself. J, Effects of FLT3-A192, CD99-A192, and co-assembled in primary patient samples obtained from USC001 (FLT3-ITD+), USC100 (Refractory/Relapse FLT3-ITD+), USC109 (FLT3-ITD + at diagnosis), and healthy donors (HDs). Mean ± SD (n = 3).